Progyny (PGNY) is back in focus after shareholders approved governance changes that remove a default supermajority voting requirement for certain deals, alongside a new $200 million share repurchase plan funded from existing cash.
See our latest analysis for Progyny.
The governance changes and the new buyback come as momentum in Progyny’s stock has picked up, with a 30-day share price return of 14.54% and a 90-day share price return of 47.53%. The 1-year total shareholder return of 26.45% contrasts with declines over the 3 and 5 year periods, suggesting recent optimism is still rebuilding from a weaker longer history.
If this kind of turnaround story has your attention, it can be useful to widen the lens and see what else is moving in healthcare related AI, starting with 38 healthcare AI stocks.
With shares up sharply in recent months, a fresh buyback in place, and the stock trading below some intrinsic value estimates, you have to ask yourself: Is Progyny still undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 13.8% Undervalued
Progyny's most followed valuation narrative pegs fair value at $30.91, above the last close of $26.63. This frames the buyback and recent rally in a different light.
Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.
Want to see what sits behind that valuation gap? The core of this narrative is how revenue, earnings and margins are modeled to evolve together. The implied future pricing power and profit profile are not what the current share price suggests. Curious which assumptions need to hold to justify that fair value.
Result: Fair Value of $30.91 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if employer benefit budgets tighten or if regulatory shifts around reproductive health make Progyny’s services harder to offer at scale.
Find out about the key risks to this Progyny narrative.
Next Steps
The tone so far is cautiously optimistic. This is your call to make, so act while the data is fresh and review the 3 key rewards.
Looking for more investment ideas?
If Progyny has sharpened your focus, do not stop here. Casting a wider net across quality stock ideas can help you spot opportunities others might overlook.
- Target resilient cash generators by checking companies in the 43 high quality undervalued stocks that combine quality fundamentals with room for potential upside.
- Prioritize staying power and sleep better at night by scanning the 68 resilient stocks with low risk scores for businesses with more stable risk profiles.
- Hunt for future standouts early by reviewing the screener containing 20 high quality undiscovered gems before the crowd catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com